Showing results (1141-1150 of 2,527) with videos related to

Sort By:
Pageof 253
Elife|May 22, 2014
Imaging the fate of histone Cse4 reveals de novo replacement in S phase and subsequent stable residence at centromeresJan Wisniewski, Bassam Hajj, Jiji Chen, et al.
International Journal of Clinical Pharmacy|August 15, 2012
Home diagnostic tests in the state of Qatar: a snapshot of public views, level of awareness and useMaguy Saffouh El Hajj, Reem Hasan El-Ajez, Muna Said Mohd Al-Ismail, et al.
Small (Weinheim an Der Bergstrasse, Germany)|February 4, 2015
Real-Time Analysis of Magnetic Hyperthermia Experiments on Living Cells under a Confocal MicroscopeVincent Connord, Pascal Clerc, Nicolas Hallali, et al.
Scientific Reports|May 31, 2018
Fabrication and In Vitro Characterization of a Tissue Engineered PCL-PLLA Heart ValveAnwarul Hasan, Sherif Soliman, Fatima El Hajj, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 22, 2023
Splenectomy in epithelial ovarian cancer surgeryHoussein El Hajj, Domenico Ferraioli, Pierre Meus, et al.
BMC Musculoskeletal Disorders|November 8, 2022
Carpal tunnel syndrome secondary to tumoral calcinosis: a case report and review of the literatureMichael Abdallah, Elie Bou Sanayeh, Rami Haroun, et al.
Frontiers in Oncology|February 21, 2025
Treatment of primary esophageal lymphomas: A reviewJoe El Khoury, Remy Daou, Neal Kim, et al.
Journal of Neuro-Oncology|November 11, 2024
The impact of adjuvant radiotherapy on overall survival in spinal low-grade gliomas: a propensity score-matched analysisVictor Gabriel El-Hajj, Sruthi Ranganathan, Harry Hoang, et al.
Journal of Cataract and Refractive Surgery|March 13, 2024
In vivo assessment of antimicrobial activity and toxicity of repeated 1% povidone-iodine applications vs a single 5% povidone-iodine applicationDavid Teren, Gil Neuman, Adi Abulafia, et al.
Breast Cancer (Dove Medical Press)|November 13, 2023
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast CancersRayan Dakroub, Solène Huard, Yara Hajj-Younes, et al.
Pageof 253